4.6 Article

Enabling Consistency in Pluripotent Stern Cell-Derived Products for Research and Development and Clinical Applications Through Material Standards

Journal

STEM CELLS TRANSLATIONAL MEDICINE
Volume 4, Issue 3, Pages 217-223

Publisher

WILEY
DOI: 10.5966/sctm.2014-0233

Keywords

-

Funding

  1. GE Healthcare
  2. Centre for Commercialization of Regenerative Medicine
  3. TAP Biosystems (now Sartorius Stedim), Lonza
  4. California Institute for Regenerative Medicine
  5. SENS Research Foundation
  6. UK Cell Therapy Catapult
  7. NIH Center for Regenerative Medicine
  8. New York Stem Cell Foundation
  9. ThermoFisher Scientific
  10. Eisai
  11. Medipost (U.S.)
  12. Medipost (Korea)
  13. Celgene
  14. Roche
  15. Oxford Biomedica
  16. Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation
  17. Technology Strategy Board
  18. MRC [MR/L01324X/1] Funding Source: UKRI
  19. Engineering and Physical Sciences Research Council [1233828] Funding Source: researchfish
  20. Medical Research Council [MR/L01324X/1] Funding Source: researchfish

Ask authors/readers for more resources

There is a need for physical standards (reference materials) to ensure both reproducibility and consistency in the production of somatic cell types from human pluripotent stem cell (hPSC) sources. We have outlined the need for reference materials (RMs) in relation to the unique properties and concerns surrounding hPSC-derived products and suggest in-house approaches to RM generation relevant to basic research, drug screening, and therapeutic applications. hPSCs have an unparalleled potential as a source of somatic cells for drug screening, disease modeling, and therapeutic application. Undefined variation and product variability after differentiation to the lineage or cell type of interest impede efficient translation and can obscure the evaluation of clinical safety and efficacy. Moreover, in the absence of a consistent population, data generated from in vitro studies could be unreliable and irreproducible. Efforts to devise approaches and tools that facilitate improved consistency of hPSC-derived products, both as development tools and therapeutic products, will aid translation. Standards exist in both written and physical form; however, because many unknown factors persist in the field, premature written standards could inhibit rather than promote innovation and translation. We focused on the derivation of physical standard RMs. We outline the need for RMs and assess the approaches to in-house RM generation for hPSC-derived products, a critical tool for the analysis and control of product variation that can be applied by researchers and developers. We then explore potential routes for the generation of RMs, including both cellular and noncellular materials and novel methods that might provide valuable tools to measure and account for variation. Multiparametric techniques to identify signatures for therapeutically relevant cell types, such as neurons and cardiomyocytes that can be derived from hPSCs, would be of significant utility, although physical RMs will be required for clinical purposes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available